Navigation Links
Oncology is the Most Active Therapeutic Area for Phase II/III R&D
Date:11/21/2013

/p>

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort
781-993-2597
ccomfort@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Genelux, a Leader in the Emerging Oncolytic Virotherapy Field, Receives Significant Industry Honor from Elsevier Business Intelligence, Identifying GL-ONC1 as One of 2013s Top Oncology Projects to Watch
2. QIAGEN Announces Partnership With Clovis Oncology to Co-develop Companion Diagnostic Targeting Drug-Resistant EGFR Mutations
3. In The Face Of Increasing Healthcare Spend And High-Cost Targeted Treatment, Market Access Barriers Continue To Rise For Targeted Oncology Drugs
4. Elekta Opens Global Education Center for Oncology and Neuroscience Professionals
5. Enhanced Strategies for Design and Execution of Biomarker-driven Oncology Trials, new life science webinar hosted by Xtalks
6. Cancer Patients to See More Precise Oncology Treatment via Innovative Life Sciences Coalition
7. Oncology Therapeutics Market in India to 2018 Report
8. Vermillions OVA1 Receives New Statement by Society of Gynecologic Oncology
9. Closed Drug Transfer Systems: Oncology Therapeutics Market Dynamics and Closed Drug Transfer Design Factors - Market Forecasts to 2017
10. Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the Annual Meeting of the American Society of Clinical Oncology
11. AbbVie Presents Results from Phase I Study of Investigational Oncology Compound ABT-199 at American Society of Clinical Oncology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... Switzerland (PRWEB) August 26, 2014 ... for drug discovery and life science research, today ... Meetings will be held in Asia, Europe, ... from global pharmaceutical companies and leading research organizations ... share best practices, case studies, and upcoming challenges ...
(Date:8/26/2014)... 2014  That,s Nice LLC, a research-focused strategic marketing ... formation of a new dedicated team that will support ... will combine current and new staff in both market ... Guy Tiene has been hired ... Tiene was previously Director of Marketing for Royal DSM,s ...
(Date:8/26/2014)... Burlington, MA (PRWEB) August 26, 2014 ... automation solutions, today announced the release of Transform ... Transform for Electronic Data Capture (EDC) product line. ... partner XClinical, and allows integration with MARVIN, the ... well as reducing study setup time, by allowing ...
(Date:8/26/2014)... August 26, 2014 Talon Innovations, a ... for the Semiconductor, Medical Device, Aerospace and other technology-driven ... the Minnesota Business magazine’s fourth annual Manufacturing Award in ... announcement in February that Talon received a grant from ... a robust new training program for its employees. ...
Breaking Biology Technology:Thought Leaders to Explore Innovations in SPR & Combination Screening at Genedata Screener User Group Meetings 2Thought Leaders to Explore Innovations in SPR & Combination Screening at Genedata Screener User Group Meetings 3That's Nice Announces Expanded Offering For Strategic Content And Public Relations 2That's Nice Announces Expanded Offering For Strategic Content And Public Relations 3Introducing Transform for MARVIN: Providing Further Flexibility for CROs and Sponsors in Partnership with XClinical 2Talon Innovations Selected as Finalist for Minnesota Business Magazine Award 2Talon Innovations Selected as Finalist for Minnesota Business Magazine Award 3
... MARINO, Calif., July 8 Epeius Biotechnologies,Corporation today ... by the U.S. Food and Drug Administration (FDA) ... including the rarity,seriousness, and current lack of effective ... and medicinal merit of Rexin-G, the,granting of Orphan ...
... MedPredict Market Research, a,global provider of pharmaceutical ... new report providing critical strategic insight,for pharma ... the market for Rheumatoid,Arthritis (RA) therapies., ... & Analysis: Rheumatoid,Arthritis Q2 2008, MedPredict,s global ...
... tests and evaluations result in 12-years of safe use. , ... St. ... and podcast released today, dietitian Mary Lee Chin describes the ... genetically modified foods. In the video, Chin discusses how consumers on a ...
Cached Biology Technology:Epeius Biotechnologies' Tumor-Targeted Rexin-G Receives FDA Orphan Drug Designation for the Treatment of Osteosarcoma 2New MedPredict Report Highlights Trend Toward Early Diagnosis and Treatment of Rheumatoid Arthritis, Impact on Pharmaceutical Development 2Dietitian Mary Lee Chin Comments on Proven Value and Safety of Food Biotechnology in New Online Video 2Dietitian Mary Lee Chin Comments on Proven Value and Safety of Food Biotechnology in New Online Video 3Dietitian Mary Lee Chin Comments on Proven Value and Safety of Food Biotechnology in New Online Video 4
(Date:8/26/2014)... mathematical sciences at New Jersey Institute of Technology (NJIT), ... clock that sets the pace for daily life. , ... other mammals with fundamental rhythms of life that include ... and with seasonal change. The brain,s circadian clock controls ... which, when disrupted by experiences such as jet lag ...
(Date:8/26/2014)... combining plasmonics and optical microresonators, researchers at the ... new optical amplifier (or laser) design, paving the ... made optical systems at the microscopic scale that ... J. Gary Eden, a professor of electrical and ... amplifiers are well-suited for routing optical power on ...
(Date:8/26/2014)... the University of Liverpool has recommended investing in dog owner ... and problems such as obesity in both people and their ... 1990, the researchers found that access to dog-friendly walking environments ... people to get out and take more exercise with their ... don,t take their dogs for a walk. In the UK, ...
Breaking Biology News(10 mins):Researching fundamental rhythms of life 2Researching fundamental rhythms of life 3Symphony of nanoplasmonic and optical resonators produces laser-like light emission 2Education and dog-friendly neighbourhoods could tackle obesity 2
... Research Center Oakland is the first children,s hospital in ... the way blood is analyzed at pediatric hospitals. This ... in some debit or credit cards at the supermarket ... The procedure starts with a respiratory therapist who ...
... A recent study conducted in the Midwestern United States ... cultivated and uncultivated soils, vastly advancing the knowledge of ... soil attribute that is related to the physical-chemical state ... processes that determine soil quality. During the wet season ...
... years after the AIDS epidemic spawned a worldwide search ... (HIV), progress in the field seems to have effectively ... a team of researchers from the California Institute of ... fact that our body,s natural HIV antibodies simply don,t ...
Cached Biology News:Children's Hospital Oakland is first pediatric hospital to use 'laboratory-on-a-card' technology 2Impact of floods on soils 2Caltech scientists show why anti-HIV antibodies are ineffective at blocking infection 2Caltech scientists show why anti-HIV antibodies are ineffective at blocking infection 3